HIGH DOSE DAUNORUBICIN (NSC-83142) IN TREATMENT OF ADVANCED ACUTE MYELOGENOUS LEUKEMIA

被引：0
|
作者：
LIPPMAN, M
ZAGER, R
HENDERSON, ES
机构：
[1] NCI, DIV CANC TREATMENT, LAB HEMATOL, BETHESDA, MD 20014 USA
[2] NCI, DIV CANC TREATMENT, LAB CHEM PHARMACOL, BETHESDA, MD 20014 USA
[3] NCI, DIV CANC TREATMENT, SUPORT CARE BRANCH, BETHESDA, MD 20014 USA
[4] NCI, DIV CANC TREATMENT, CANC THERAPY EVALUATION BRANCH, BETHESDA, MD 20014 USA
来源：
CANCER CHEMOTHERAPY REPORTS PART 1 | 1972年 / 56卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：755 / 760
页数：6
相关论文
共 50 条
  • [1] DAUNORUBICIN (NSC-83142) IN ADVANCED CHILDHOOD LEUKEMIA
    JAFFE, N
    TRAGGIS, DG
    DAS, L
    CANCER CHEMOTHERAPY REPORTS PART 1, 1974, 58 (05): : 661 - 665
  • [2] CYTOSINE-ARABINOSIDE (NSC-63878) AND DAUNORUBICIN (NSC-83142) THERAPY IN ACUTE NONLYMPHOCYTIC LEUKEMIA
    YATES, JW
    WALLACE, HJ
    ELLISON, RR
    HOLLAND, JF
    CANCER CHEMOTHERAPY REPORTS PART 1, 1973, 57 (04): : 485 - 488
  • [3] DAUNORUBICIN (NSC-83142) VERSUS DAUNORUBICIN PLUS PREDNISONE (NSC-10023) VERSUS DAUNORUBICIN PLUS VINCRISTINE (NSC-67574) PLUS PREDNISONE IN ADVANCED CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA
    JONES, B
    ICUTTNER, J
    LEVY, RN
    PATTERSON, RB
    KUNG, F
    PLEUSS, HJ
    FALKSON, G
    TREAT, CL
    HAURANI, F
    BUGERT, EO
    ROSNER, F
    CAREY, RW
    LUKENS, J
    BLOM, J
    DEGNAN, TJ
    WOHL, H
    GLIDEWELL, O
    HOLLAND, JF
    CANCER CHEMOTHERAPY REPORTS PART 1, 1972, 56 (06): : 729 - 737
  • [4] COMPARISON OF DAUNORUBICIN (NSC-83142) WITH ADRIAMYCIN (NSC-123127) IN TREATMENT OF LATE-STAGE CHILDHOOD SOLID TUMORS
    EVANS, AE
    BAEHNER, RL
    CHARD, RL
    LEIKIN, SL
    PANG, EM
    PIERCE, M
    CANCER CHEMOTHERAPY REPORTS PART 1, 1974, 58 (05): : 671 - 676
  • [5] SOME DETERMINANTS OF THERAPEUTIC EFFICACY OF ACTINOMYCIN-D (NSC-3053), ADRIAMYCIN (NSC-123127), AND DAUNORUBICIN (NSC-83142)
    SCHWARTZ, HS
    CANCER CHEMOTHERAPY REPORTS PART 1, 1974, 58 (01): : 55 - 62
  • [6] HIGH-DOSE CYTARABINE AND DAUNORUBICIN INDUCTION AND POSTREMISSION CHEMOTHERAPY FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA IN ADULTS
    PHILLIPS, GL
    REECE, DE
    SHEPHERD, JD
    BARNETT, MJ
    BROWN, RA
    FREILAHR, DA
    KLINGEMANN, HG
    BOLWELL, BJ
    SPINELLI, JJ
    HERZIG, RH
    HERZIG, GP
    BLOOD, 1991, 77 (07) : 1429 - 1435
  • [7] SEQUENCING OF CYTOSINE-ARABINOSIDE (NSC-63878) AND DAUNORUBICIN (NSC-82151) IN ACUTE MYELOGENOUS LEUKEMIA
    OMURA, GA
    CANCER TREATMENT REPORTS, 1976, 60 (05): : 629 - 631
  • [8] DAUNORUBICIN (NSC-82151) IN TREATMENT OF ADVANCED CHILDHOOD LYMPHOBLASTIC LEUKEMIA
    JONES, B
    HOLLAND, JF
    MORRISON, AR
    LEE, SL
    SINKS, LF
    CUTTNER, J
    RAUSEN, A
    KUNG, F
    PLUSS, HJ
    HAURANI, FI
    PATTERSON, RB
    BLOM, J
    BURGERT, EO
    MOON, JH
    CHEVALIER, L
    SAWITSKY, A
    ALBALA, MM
    FORCIER, RJ
    FALKSON, G
    GLIDEWELL, O
    CANCER RESEARCH, 1971, 31 (02) : 84 - +
  • [9] DAUNORUBICIN OR DOXORUBICIN IN ACUTE MYELOGENOUS LEUKEMIA
    GALE, RP
    FOON, KA
    LEUKEMIA, 1988, 2 (04) : 209 - 210
  • [10] POSTREMISSION CHEMOTHERAPY FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA - IMPROVED SURVIVAL WITH HIGH-DOSE CYTARABINE AND DAUNORUBICIN CONSOLIDATION TREATMENT
    CHAMPLIN, R
    GAJEWSKI, J
    NIMER, S
    VOLLSET, S
    LANDAW, E
    WINSTON, D
    SCHILLER, G
    HO, W
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1199 - 1206
12345